Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | Article

From the Editorial Board: Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

13-11-2018 | Ankylosing spondylitis | Highlight | News

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

medwireNews@ACR/ARHP 2018

medwireNews was at the 2018 ACR/ARHP Annual Meeting in Chicago. Click through for the latest news and expert interviews.

Latest from across the site

16-11-2018 | Rheumatoid arthritis | News

News in brief

Subcutaneous, intravenous tocilizumab similarly effective in RA

The subcutaneous and intravenous formulations of tocilizumab have comparable effectiveness, real-world study results suggest.

15-11-2018 | Etanercept biosimilar | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213474

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Author:
Eoin Feeney

13-11-2018 | Ankylosing spondylitis | Highlight | News

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

Source:

J Rheumatol 2018; doi:10.3899/jrheum.180312

12-11-2018 | Rheumatoid arthritis | News

News in brief

Further support for 3-month assessment to guide DMARD adjustment in RA patients

Measuring disease activity at 3 months can help predict DMARD response at 6 months in patients with rheumatoid arthritis, researchers report.

09-11-2018 | Juvenile idiopathic arthritis | News

News in brief

Activity tracking ‘feasible’ for adolescents with JIA

Findings from a pilot study indicate that activity tracking using a wrist-worn device is a feasible approach for promoting physical activity in adolescent patients with juvenile idiopathic arthritis

Meet our Editorial Board

New Content Item Meet our Advisory Board

image credits